NGS Oncology Market - A Global and Regional Analysis: Focus on Offering, Sequencing Technology, Workflow, Application, End User, and Region - Analysis and Forecast, 2022-2032
Global NGS Oncology Market Industry Overview
The global NGS oncology market is projected to reach $51,783.0 million in 2032 from 14,828.6 million in 2021, witnessing a CAGR of 12.04% during the forecast period 2022-2032. The growth in the NGS oncology market is expected to be driven by an increasing number of panels or kits, bioinformatics services for computational analysis, and a rising number of open-source free sequencing platform providers offering NGS oncology.
Market Lifecycle Stage
The NGS oncology market is a well-developed market with an integral part of medical decision-making, which aid in acquiring information for a wide range of treatment dissemination, accentuating their criticality in healthcare. The NGS oncology has a critical role in the precision medicine approach, as it ensures the safe and effective application of targeted therapeutics. Most global NGS oncology players offer products encompassing the kits, platforms, and services.
Increasing investments in the R&D for NGS oncology is one of the significant global NGS oncology market opportunities. Several diagnostics and pharmaceutical companies are working collaboratively to adopt next-generation sequencing (NGS) in the field of oncology.
Impact
The presence of major product and service providers of NGS oncology and services in regions such as North America and Europe significantly impacts the market. For instance, Illumina, Inc. provides an NGS sequencing platform and clinical sequencing bioinformatics services.
Companies such as Thermo Fisher Scientific Inc. expanded hematology oncology portfolio NGS with new Ion Torrent Oncomine Immune Repertoire Assays that ensure quality results. The presence of these companies has a positive impact on market growth.
Impact of COVID-19
The current global NGS oncology market study comprises next-generation sequencing (NGS)-based products and services for oncology used for diagnosing cancer, measuring cancer risk, and aiding in providing the right and personalized treatment to cancer patients. Since the market is primarily dominated by manufacturers of next-generation sequencing instruments, kits, assays, and service providers that provide gene panels and testing services using next-generation sequencing for oncology, the pandemic negatively impacted the growth of revenue generated from the market. Players in the NGS oncology market reported a decline in revenues during the initial phase of the pandemic. The decrease was primarily attributed to the lockdown in the regions that disrupted the supply chain, thereby hampering the cancer diagnostic testing.
Additionally, a halt in research and development activities pertaining to the use of next-generation sequencing for oncology to discover novel variants and develop novel products and services for the market also led to a decline in revenue. However, to curb the spread of the SARS-CoV-2 virus and contain the spread of the virus, demand for COVID-19 tests and services that detects the virus in less time increased, which led to the shift in focus of the manufacturers and service providers for developing and manufacturing testing kits and services for the detection of SARS-CoV-2 virus.
Market Segmentation:
Segmentation 1: by Sequencing Technology
Targeted Sequencing
Genomics
Transcriptomics
Epigenomics
The global NGS oncology market (by sequencing technology) is dominated by targeted sequencing in 2021. The segment is expected to maintain its dominance throughout the forecast period 2022-2032. Genomics held the second largest market share, followed by epigenomics and transcriptomics.
Segmentation 2: by Offering
Platform
Kits
Services
The global NGS oncology market (by offering) is dominated by kits, followed by platform and services. The kits segment is expected to maintain its dominance throughout the forecast period 2022-2032.
Segmentation 3: by Workflow
Pre-Sequencing
Sequencing
Data Analysis
The global NGS oncology market (by workflow) is dominated by pre-sequencing, followed by sequencing and data analysis. The pre-sequencing segment is expected to maintain its dominance during the forecast period 2022-2032.
Segmentation 4: by Application
Genetic Screening
Hereditary Genetic Testing
Hematological Malignancies
Solid Tumors
Other Applications
The global NGS oncology market (by application) is dominated by hereditary genetic testing, which is expected to maintain its dominance during the forecast period 2022-2032. The solid tumors segment holds the second position in market share, followed by hematological malignancies and genetic screening in 2021.
Segmentation 5: by End User
Hospitals and Clinics
Clinical Research Organizations (CROs)
Academic and Research Institutes
Pharmaceutical and Biotechnology Companies
Other End Users
The global NGS oncology market (by end user) is dominated by hospitals and clinics, followed by pharmaceutical and biotechnology companies. The hospitals and clinics segment is expected to maintain its dominance during the forecast period 2022-2032.
Segmentation 6: by Region
North America
Europe
Asia-Pacific
Latin America
Rest-of-the-World
North America generated the highest revenue of $6,386.9 million in 2021 and dominated the global NGS oncology market. The population of North America suffers from various diseases and rising healthcare costs. The government is extensively supporting research organizations with projects aimed at improving the understanding and treatment of cancer patients.
Recent Developments in the Global NGS Oncology Market
In October 2021, F. Hoffmann-La Roche Ltd. announced the launch of the AVENIO Tumor Tissue Comprehensive Genomic Profiling (CGP) Kit that allows laboratories to expand their in-house precision cancer research, gain meaningful genomic insights, and enhance their understanding of cancer biology. The kit is the first co-developed product by F. Hoffmann-La Roche Ltd. and Foundation Medicine, bringing in the expertise of both companies in genomic science. With the launch of the kit, the company anticipates significant expansion in access to genomic profiling globally and strengthens the company's ability to act as an essential partner to researchers working on cancer care.
In September 2021, Thermo Fisher Scientific Inc. introduced the Applied Biosystems QuantStudio Absolute Q Digital PCR System, the first fully integrated digital PCR (dPCR) system designed to deliver highly accurate and consistent results in 90 minutes, excels in cancer research and other fields.
In September 2020, Agilent Technologies, Inc. launched a product new Agilent SureSelect XT HS2 DNA Kit designed to address challenges faced by researchers while preparing DNA sequencing libraries. The kit represents state-of-art library preparation and target enrichment.
Demand – Drivers and Limitations
Following are the demand drivers for the global NGS Oncology Market:
Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques
Reducing Cost of Sequencing
Rapid Technological Advancements Related to NGS Oncology
The market is expected to face some limitations too due to the following challenges:
Inadequate NGS Oncology Reimbursement Scenario
Increasing Cost of NGS Automated Sample Preparation Instruments
Barriers in the Advancement of NGS Oncology
How Can This Report Add Value to an Organization?
Product/Innovation Strategy: Major manufacturers of the global NGS oncology market, along with the service providers, are actively involved in undertaking significant business strategies to translate success in research and development into the commercial clinical setting.
Growth/Marketing Strategy: Owing to the explosion of massively parallel sequencing and its applications, all areas of medicine have been affected, particularly oncology. NGS sequencing has gradually evolved from conventional sequencing to a fully integrated digital PCR (dPCR) system designed to deliver extremely accurate and consistent results in 90 minutes, which excels in cancer research and other fields.
Competitive Strategy: Key players in the global NGS oncology market analyzed and profiled in the study have been involved as the NGS oncology-based product and services manufacturers that provide kits or panel and software services. Moreover, a detailed competitive benchmarking of the players operating in the global NGS oncology market has been done to help the reader understand how players stack against each other, presenting a clear market landscape. Additionally, comprehensive competitive strategies such as partnerships, agreements, and collaborations will aid the reader in understanding the untapped revenue pockets in the market.
Key Market Players and Competition Synopsis
The companies that are profiled have been selected based on inputs gathered from primary experts and analyzing company coverage, product portfolio, and market penetration.
Some prominent names established in this market are:
Agilent Technologies, Inc.
Bio-Rad Laboratories, Inc.
Biodesix, Inc.
Caris Life Sciences
DNASTAR
Fulgent Genetics, Inc.
F. Hoffmann-La Roche Ltd
Illumina, Inc.
Invitae Corporation
IntegraGen (OncoDNA)
Oxford Nanopore Technologies plc.
Pacific Biosciences of California, Inc.
PerkinElmer, Inc.
Pillar Biosciences, Inc.
QIAGEN N.V.
Thermo Fisher Scientific Inc.
Takara Bio Inc.
Vela Diagnostics
*PDF email from publisher allows for 1-3 users, with permission to print*
- 1 Markets
- 1.1 Product Definition
- 1.1.1 Inclusion and Exclusion Criteria
- 1.2 Market Scope
- 1.2.1 Scope of the Study
- 1.2.2 Key Questions Answered in the Report
- 1.3 Research Methodology
- 1.3.1 Global NGS Oncology Market: Research Methodology
- 1.3.2 Data Sources
- 1.3.2.1 Primary Data Sources
- 1.3.2.2 Secondary Data Sources
- 1.3.3 Market Estimation Model
- 1.3.4 Criteria for Company Profiling
- 1.4 Global NGS Oncology Market: Overview
- 1.4.1 Market Size and Growth Potential, $Million, 2021-2032
- 1.4.2 COVID-19 Impact on Global NGS Oncology Market
- 1.5 Global NGS Oncology Market: Patent Landscape
- 1.5.1 Patent Filing Trend
- 1.5.2 Patent Analysis (by Year)
- 1.5.3 Patent Analysis (by Region)
- 1.5.4 Patent Analysis (by Country)
- 2 Industry Analysis
- 2.1 Overview
- 2.2 Regulatory Framework in the U.S.
- 2.2.1 FDA Regulation
- 2.2.2 Centers for Medicaid and Medicare Services (CMS) Regulation
- 2.3 Regulatory Framework in European Union (EU)
- 2.4 Regulatory Framework in Asia-Pacific
- 2.4.1 China
- 2.4.2 Japan
- 3 Market Dynamics
- 3.1 Market Dynamics
- 3.1.1 Overview
- 3.2 Impact Analysis
- 3.3 Market Drivers
- 3.3.1 Increasing Incidence of Cancer Requiring Sophisticated Molecular Techniques
- 3.3.2 Reducing Cost of Sequencing
- 3.3.3 Rapid Technological Advancements Related to NGS Oncology
- 3.4 Market Challenges
- 3.4.1 Inadequate NGS Oncology Reimbursement Scenario
- 3.4.2 Increasing Cost of NGS Automated Sample Preparation Instruments
- 3.4.3 Barriers in the Advancement of NGS Oncology
- 3.5 Market Opportunities
- 3.5.1 Informatics and Technology Advancement for A Large Number of Customers
- 3.5.2 Rising Number of Initiatives for NGS Oncology Research
- 4 Competitive Landscape
- 4.1 Overview
- 4.2 Corporate Strategies
- 4.2.1 Mergers and Acquisitions
- 4.2.2 Synergistic Activities
- 4.2.3 Business Expansion and Funding Activities
- 4.3 Business Strategies
- 4.3.1 Product Launches/Approvals
- 4.3.2 Product Upgradation
- 4.4 Market Share Analysis (by Company)
- 4.5 Growth-Share Analysis (by Application)
- 5 Offerings, $Million, 2021-2032
- 5.1 Overview
- 5.1.1 Platform
- 5.1.2 Kits
- 5.1.3 Services
- 6 Sequencing Technology, $Million, 2021-2032
- 6.1 Overview
- 6.1.1 Targeted Sequencing
- 6.1.2 Genomics
- 6.1.2.1 Whole-Genome Sequencing (WGS)
- 6.1.2.2 Whole-Exome Sequencing (WES)
- 6.1.3 Transcriptomics
- 6.1.4 Epigenomics
- 6.1.4.1 ChIP-Sequencing (ChIP-Seq)
- 6.1.4.2 Bisulfite Sequencing
- 7 Workflow, $Million, 2021-2032
- 7.1 Overview
- 7.1.1 Pre-Sequencing
- 7.1.1.1 Sample Extraction/Isolation
- 7.1.1.2 Library Preparation
- 7.1.1.3 Target Enrichment
- 7.1.2 Sequencing
- 7.1.3 Data Analysis
- 7.1.3.1 Secondary Analysis
- 7.1.3.2 Tertiary Analysis
- 8 Applications, $Million, 2021-2032
- 8.1 Overview
- 8.2 Genetic Screening
- 8.3 Hereditary Genetic Testing
- 8.4 Hematological Malignancies
- 8.4.1 Leukemia
- 8.4.2 Lymphoma
- 8.4.3 Multiple Myeloma
- 8.4.4 Other Hematological Malignancies
- 8.5 Solid Tumors
- 8.5.1 Breast Cancer
- 8.5.2 Lung Cancer
- 8.5.3 Colorectal Cancer
- 8.5.4 Prostate Cancer
- 8.5.5 Thyroid Cancer
- 8.5.6 Endometrial Cancer
- 8.5.7 Lymphoma
- 8.5.8 Melanoma
- 8.5.9 Brain Cancer
- 8.5.10 Other Solid Tumors
- 8.6 Other Applications
- 9 End Users, $Million, 2021-2032
- 9.1 Overview
- 9.2 Hospitals and Clinics
- 9.3 Clinical Research Organizations (CROs)
- 9.4 Academic and Research Institutes
- 9.5 Pharmaceutical and Biotechnology Companies
- 9.6 Other End Users
- 10 Region, $Million, 2021-2032
- 10.1 Overview
- 10.2 North America
- 10.2.1 U.S.
- 10.2.2 Canada
- 10.3 Europe
- 10.3.1 Germany
- 10.3.2 France
- 10.3.3 U.K.
- 10.3.4 Italy
- 10.3.5 Netherlands
- 10.3.6 Spain
- 10.3.7 Rest-of-Europe
- 10.4 Asia-Pacific
- 10.4.1 China
- 10.4.2 Japan
- 10.4.3 India
- 10.4.4 Australia
- 10.4.5 South Korea
- 10.4.6 Singapore
- 10.4.7 Rest-of-Asia-Pacific
- 10.5 Latin America
- 10.5.1 Brazil
- 10.5.2 Mexico
- 10.5.3 Rest-of-Latin America
- 10.6 Rest-of-the-World
- 11 Company Profiles
- 11.1 Overview
- 11.2 Agilent Technologies, Inc.
- 11.2.1 Company Overview
- 11.2.2 Role of Agilent Technologies, Inc. in the Global NGS Oncology Market
- 11.2.3 Key Customers of the Company
- 11.2.4 Key Competitors of the Company
- 11.2.5 Financials
- 11.2.6 Key Insights about the Financial Health of the Company
- 11.2.7 Corporate Strategies
- 11.2.7.1 Mergers and Acquisitions
- 11.2.7.2 Business Expansion and Funding
- 11.2.8 Business Strategies
- 11.2.8.1 Agilent Technologies, Inc.: Product Launch/Approval
- 11.2.9 Analyst Perspective
- 11.3 Bio-Rad Laboratories, Inc.
- 11.3.1 Company Overview
- 11.3.2 Role of Bio-Rad Laboratories, Inc. in the Global NGS Oncology Market
- 11.3.3 Key Customers of the Company
- 11.3.4 Key Competitors of the Company
- 11.3.5 Financials
- 11.3.6 Key Insights about the Financial Health of the Company
- 11.3.7 Business Strategies
- 11.3.7.1 Product Launch/ Approval
- 11.3.8 Analyst Perspective
- 11.4 Biodesix, Inc.
- 11.4.1 Company Overview
- 11.4.2 Role of Biodesix, Inc. in the Global NGS Oncology Market
- 11.4.3 Key Customers of the Company
- 11.4.4 Key Competitors of the Company
- 11.4.5 Financials
- 11.4.6 Key Insights about the Financial Health of the Company
- 11.4.7 Corporate Strategies
- 11.4.7.1 Synergistic Activities
- 11.4.8 Analyst Perspective
- 11.5 Caris Life Sciences
- 11.5.1 Company Overview
- 11.5.2 Role of Caris Life Sciences in the Global NGS Oncology Market
- 11.5.3 Key Customers of the Company
- 11.5.4 Key Competitors of the Company
- 11.5.5 Analyst Perspective
- 11.6 DNASTAR
- 11.6.1 Company Overview
- 11.6.2 Role of DNASTAR in the Global NGS Oncology Market
- 11.6.3 Key Customers of the Company
- 11.6.4 Key Competitors of the Company
- 11.6.5 Corporate Strategies
- 11.6.5.1 Mergers and Acquisitions
- 11.6.6 Business Strategies
- 11.6.6.1 Product Launch/Approval
- 11.6.7 Analyst Perspective
- 11.7 Fulgent Genetics, Inc.
- 11.7.1 Company Overview
- 11.7.2 Role of Fulgent Genetics, Inc. in the Global NGS Oncology Market
- 11.7.3 Key Customers of the Company
- 11.7.4 Key Competitors of the Company
- 11.7.5 Financials
- 11.7.6 Key Insights about the Financial Health of the Company
- 11.7.7 Corporate Strategies
- 11.7.7.1 Business Expansion
- 11.7.8 Analyst Perspective
- 11.8 F. Hoffmann-La Roche Ltd
- 11.8.1 Company Overview
- 11.8.2 Role of F. Hoffmann-La Roche Ltd in the Global NGS Oncology Market
- 11.8.3 Key Customers of the Company
- 11.8.4 Key Competitors of the Company
- 11.8.5 Financials
- 11.8.6 Key Insights about the Financial Health of the Company
- 11.8.7 Corporate Strategies
- 11.8.7.1 Synergistic Activities
- 11.8.8 Business Strategies
- 11.8.8.1 Product Launch
- 11.8.9 Analyst Perspective
- 11.9 Illumina, Inc.
- 11.9.1 Company Overview
- 11.9.2 Role of Illumina, Inc. in the Global NGS Oncology Market
- 11.9.3 Key Customers of the Company
- 11.9.4 Key Competitors of the Company
- 11.9.5 Financials
- 11.9.6 Key Insights about the Financial Health of the Company
- 11.9.7 Corporate Strategies
- 11.9.7.1 Synergistic Activities
- 11.9.8 Analyst Perspective
- 11.1 Invitae Corporation
- 11.10.1 Company Overview
- 11.10.2 Role of Invitae Corporation in the Global NGS Oncology Market
- 11.10.3 Key Customers of the Company
- 11.10.4 Key Competitors of the Company
- 11.10.5 Financials
- 11.10.6 Key Insights about the Financial Health of the Company
- 11.10.7 Business Strategies
- 11.10.7.1 Product Launch
- 11.10.8 Analyst Perspective
- 11.11 IntegraGen (OncoDNA)
- 11.11.1 Company Overview
- 11.11.2 Role of IntegraGen (OncoDNA) in the Global NGS Oncology Market
- 11.11.3 Key Customers of the Company
- 11.11.4 Key Competitors of the Company
- 11.11.5 Business Strategies
- 11.11.5.1 Product Launch/ Approval
- 11.11.6 Analyst Perspective
- 11.12 Oxford Nanopore Technologies plc.
- 11.12.1 Company Overview
- 11.12.2 Role of Oxford Nanopore Technologies plc. in the Global NGS Oncology Market
- 11.12.3 Key Customers of the Company
- 11.12.4 Key Competitors of the Company
- 11.12.5 Financials
- 11.12.6 Key Insights about the Financial Health of the Company
- 11.12.7 Corporate Strategies
- 11.12.7.1 Synergistic Activities
- 11.12.8 Business Strategies
- 11.12.8.1 Product Launch/ Approval
- 11.12.9 Analyst Perspective
- 11.13 Pacific Biosciences of California, Inc.
- 11.13.1 Company Overview
- 11.13.2 Role of Pacific Biosciences of California, Inc. in the Global NGS Oncology Market
- 11.13.3 Key Customers of the Company
- 11.13.4 Key Competitors of the Company
- 11.13.5 Financials
- 11.13.6 Key Insights about the Financial Health of the Company
- 11.13.7 Corporate Strategies
- 11.13.7.1 Mergers and Acquisitions
- 11.13.7.2 Synergistic Activities
- 11.13.8 Analyst Perspective
- 11.14 PerkinElmer, Inc.
- 11.14.1 Company Overview
- 11.14.2 Role of PerkinElmer, Inc. in the Global NGS Oncology Market
- 11.14.3 Key Customers of the Company
- 11.14.4 Key Competitors of the Company
- 11.14.5 Financials
- 11.14.6 Key Insights about the Financial Health of the Company
- 11.14.7 Analyst Perspective
- 11.15 Pillar Biosciences, Inc.
- 11.15.1 Company Overview
- 11.15.2 Role of Pillar Biosciences, Inc., in the Global NGS Oncology Market
- 11.15.3 Key Customers of the Company
- 11.15.4 Key Competitors of the Company
- 11.15.5 Corporate Strategies
- 11.15.5.1 Synergistic Activities
- 11.15.6 Business Strategies
- 11.15.6.1 Product Launch/Approval
- 11.15.7 Analyst Perspective
- 11.16 QIAGEN N.V.
- 11.16.1 Company Overview
- 11.16.2 Role of QIAGEN N.V. in the Global NGS Oncology Market
- 11.16.3 Key Customers of the Company
- 11.16.4 Key Competitors of the Company
- 11.16.5 Financials
- 11.16.6 Key Insights about the Financial Health of the Company
- 11.16.7 Corporate Strategies
- 11.16.7.1 Synergistic Activities
- 11.16.8 Business Strategies
- 11.16.8.1 Product Launch/Approvals
- 11.16.9 Analyst Perspective
- 11.17 Thermo Fisher Scientific Inc.
- 11.17.1 Company Overview
- 11.17.2 Role of Thermo Fisher Scientific Inc. in the Global NGS Oncology Market
- 11.17.3 Customers of the Company
- 11.17.4 Key Competitors of the Company
- 11.17.5 Financials
- 11.17.6 Key Insights about the Financial Health of the Company
- 11.17.7 Corporate Strategies
- 11.17.7.1 Mergers and Acquisitions
- 11.17.7.2 Synergistic Activities
- 11.17.7.3 Business Expansion and Funding
- 11.17.8 Business Strategies
- 11.17.8.1 Product Launch/Approval
- 11.17.9 Analyst Perspective
- 11.18 Takara Bio Inc.
- 11.18.1 Company Overview
- 11.18.2 Role of Takara Bio Inc. in the Global NGS Oncology Market
- 11.18.3 Key Customers of the Company
- 11.18.4 Key Competitors of the Company
- 11.18.5 Financials
- 11.18.6 Key Insights about the Financial Health of the Company
- 11.18.7 Analyst Perspective
- 11.19 Vela Diagnostics
- 11.19.1 Company Overview
- 11.19.2 Role of Vela Diagnostics in the Global NGS Oncology Market
- 11.19.3 Key Customers of the Company
- 11.19.4 Key Competitors of the Company
- 11.19.5 Business Strategies
- 11.19.5.1 Product Launch/ Approval
- 11.19.6 Analyst Perspective
- List of Figures
- Figure 1: Global NGS Oncology Market, $Million, 2021 and 2032
- Figure 2: Impact Analysis of Market Drivers and Challenges on the Global NGS Oncology Market
- Figure 3: Global NGS Oncology Market Segmentation
- Figure 4: Global NGS Oncology Market Share (by Sequencing Technology), $Million, 2021 and 2032
- Figure 5: Global NGS Oncology Market Share (by Workflow), $Million, 2021 and 2032
- Figure 6: Global NGS Oncology Market Share (by Application), $Million, 2021 and 2032
- Figure 7: Global NGS Oncology Market Share (by End User), $Million, 2021 and 2032
- Figure 8: Global NGS Oncology Market Snapshot (by Region), 2021
- Figure 9: Global NGS Oncology Market Segmentation
- Figure 10: Global NGS Oncology Market: Research Methodology
- Figure 11: Primary Research Methodology
- Figure 12: Bottom-Up Approach (Segment-Wise Analysis)
- Figure 13: Top-Down Approach (Segment-Wise Analysis)
- Figure 14: Global NGS Oncology Market, $Million, 2021-2032
- Figure 15: Impact of COVID-19 on the Global NGS Oncology Market
- Figure 16: Year-Wise Analysis of Patents Related to NGS Oncology, January 2019-January 2022
- Figure 17: Region-Wise Analysis of Patents Related to NGS Oncology, January 2019-January 2022
- Figure 18: Country-Wise Analysis of Patents Related to NGS Oncology, January 2019-January 2022
- Figure 19: Overview of Regulatory Process for Medical Devices by the FDA
- Figure 20: Europe’s IVD Regulatory Approval Process
- Figure 21: Medical Device Regulatory Approval Process in China
- Figure 22: Global NGS Oncology Market Dynamics
- Figure 23: Global Cancer Incidence 2017- 2021
- Figure 24: Reducing Cost and Increasing Output (TB) of Genome Sequencing (2009-2025)
- Figure 25: Reportable Barriers in the Advancement of Global NGS Oncology Market
- Figure 26: Share of Key Development Activities, January 2019-January 2022
- Figure 27: Share of Mergers and Acquisitions (by Company), January 2019-January 2022
- Figure 28: Share of Synergistic Activities (by Company), January 2019-January 2022
- Figure 29: Share of Business Expansion and Funding Activities (by Company), January 2019- January 2022
- Figure 30: Share of Product Launches/Approvals (by Company), January 2019-January 2022
- Figure 31: Share of Product Upgradation (by Company), January 2019-January 2022
- Figure 32: Market Share Analysis of Global NGS Oncology Market (by Company), 2021
- Figure 33: Growth-Share Analysis of Global NGS Oncology Market (by Application), 2022-2032
- Figure 34: Global NGS Oncology Market (by Offering)
- Figure 35: Global NGS Oncology Market (by Offering), $Million, 2021 and 2032
- Figure 36: Global NGS Oncology Market (Platform), $Million, 2021-2032
- Figure 37: Global NGS Oncology Market (Kits), $Million, 2021-2032
- Figure 38: Global NGS Oncology Market (Services), $Million, 2021-2032
- Figure 39: Global NGS Oncology Market (by Sequencing Technology)
- Figure 40: Global NGS Oncology Market (by Sequencing Technology), $Million, 2021 and 2032
- Figure 41: Global NGS Oncology Market (Targeted Sequencing), $Million, 2021-2032
- Figure 42: Global NGS Oncology Market (Genomics), $Million, 2021-2032
- Figure 43: Global NGS Oncology Market (Whole-Genome Sequencing), $Million, 2021-2032
- Figure 44: Global NGS Oncology Market (Whole-Exome Sequencing), $Million, 2021-2032
- Figure 45: Global NGS Oncology Market (Transcriptomics), $Million, 2021-2032
- Figure 46: Global NGS Oncology Market (Epigenomics), $Million, 2021-2032
- Figure 47: Global NGS Oncology Market (ChIP-Sequencing), $Million, 2021-2032
- Figure 48: Global NGS Oncology Market (Bisulfite Sequencing), $Million, 2021-2032
- Figure 49: Global NGS Oncology Market (by Workflow)
- Figure 50: Global NGS Oncology Market (by Workflow), $Million, 2021 and 2032
- Figure 51: Global NGS Oncology Market (Pre-Sequencing), $Million, 2021-2032
- Figure 52: Global NGS Oncology Market (Sample Extraction/Isolation), $Million, 2021-2032
- Figure 53: General Workflow of Next-Generation Sequencing Library Preparation
- Figure 54: Global NGS Oncology Market (Library Preparation), $Million, 2021-2032
- Figure 55: Different Types of Target Enrichment Techniques
- Figure 56: Global NGS Oncology Market (Target Enrichment), $Million, 2021-2032
- Figure 57: Global NGS Oncology Market (Sequencing), $Million, 2021-2032
- Figure 58: Global NGS Oncology Market (Data Analysis), $Million, 2021-2032
- Figure 59: Global NGS Oncology Market (Secondary Analysis), $Million, 2021-2032
- Figure 60: Global NGS Oncology Market (Tertiary Analysis), $Million, 2021-2032
- Figure 61: Global NGS Oncology Market (by Application), $Million, 2021 and 2032
- Figure 62: Challenges Faced Using NGS in Genetic Screening
- Figure 63: Global NGS Oncology Market (Genetic Screening), $Million, 2021-2032
- Figure 64: Global NGS Oncology Market (Hereditary Genetic Testing), $Million, 2021-2032
- Figure 65: Global NGS Oncology Market (Hematological Malignancies), $Million, 2021-2032
- Figure 66: Global NGS Oncology Market (Leukemia) $Million, 2021-2032
- Figure 67: Global NGS Oncology Market (Lymphoma), $Million, 2021-2032
- Figure 68: Global NGS Oncology Market (Multiple Myeloma), $Million, 2021-2032
- Figure 69: Global NGS Oncology Market (Other Hematological Malignancies), $Million, 2021-2032
- Figure 70: Global NGS Oncology Market (Solid Tumors), $Million, 2021-2032
- Figure 71: Global NGS Oncology Market (Breast Cancer), $Million, 2021-2032
- Figure 72: Global NGS Oncology Market (Lung Cancer), $Million, 2021-2032
- Figure 73: Global NGS Oncology Market (Colorectal Cancer), $Million, 2021-2032
- Figure 74: Global NGS Oncology Market (Prostate Cancer), $Million, 2021-2032
- Figure 75: Global NGS Oncology Market (Thyroid Cancer), $Million, 2021-2032
- Figure 76: Global NGS Oncology Market (Endometrial Cancer), $Million, 2021-2032
- Figure 77: Global NGS Oncology Market (Lymphoma), $Million, 2021-2032
- Figure 78: Global NGS Oncology (Melanoma), $Million, 2021-2032
- Figure 79: Global NGS Oncology Market (Brain Cancer), $Million, 2021-2032
- Figure 80: Global NGS Oncology Market (Other Solid Tumors), $Million, 2021-2032
- Figure 81: Global NGS Oncology Market (Other Applications), $Million, 2021-2032
- Figure 82: Global NGS Oncology Market (by End User), $Million, 2021- 2032
- Figure 83: Global NGS Oncology Market (Hospitals and Clinics), $Million, 2021-2032
- Figure 84: Global NGS Oncology Market (Clinical Research Organizations), $Million, 2021-2032
- Figure 85: Global NGS Oncology Market (Academic and Research Institutes), $Million, 2021-2032
- Figure 86: Global NGS Oncology Market (Pharmaceutical and Biotechnology Companies), $Million, 2021-2032
- Figure 87: Global NGS Oncology Market (Other End Users), $Million, 2021-2032
- Figure 88: Global NGS Oncology Market Snapshot (by Region), $Million, 2021
- Figure 89: Global NGS Oncology Market Share (by Region), $Million, 2021 and 2032
- Figure 90: Global NGS Oncology Market (North America), $Million, 2021-2032
- Figure 91: U.S. NGS Oncology Market, $Million, 2021-2032
- Figure 92: Canada NGS Oncology Market, $Million, 2021-2032
- Figure 93: Europe NGS Oncology Market, $Million, 2021-2032
- Figure 94: Europe NGS Oncology Market Share (by Country), $Million, 2021 and 2032
- Figure 95: Germany NGS Oncology Market, $Million, 2021-2032
- Figure 96: France NGS Oncology Market, $Million, 2021-2032
- Figure 97: U.K. NGS Oncology Market, $Million, 2021-2032
- Figure 98: Italy NGS Oncology Market, $Million, 2021-2032
- Figure 99: Netherlands NGS Oncology Market, $Million, 2021-2032
- Figure 100: Spain NGS Oncology Market, $Million, 2021-2032
- Figure 101: Rest-of-Europe NGS Oncology Market, $Million, 2021-2032
- Figure 102: Asia-Pacific NGS Oncology Market, $Million, 2021-2032
- Figure 103: Asia-Pacific NGS Oncology Market Share (by Country), $Million, 2021 and 2032
- Figure 104: China NGS Oncology Market, $Million, 2021-2032
- Figure 105: Japan NGS Oncology Market, $Million, 2021-2032
- Figure 106: India NGS Oncology Market, $Million, 2021-2032
- Figure 107: Australia NGS Oncology Market, $Million, 2021-2032
- Figure 108: South Korea NGS Oncology Market, $Million, 2021-2032
- Figure 109: Singapore NGS Oncology Market, $Million, 2021-2032
- Figure 110: Rest-of-Asia-Pacific (RoAPAC) NGS Oncology Market, $Million, 2021-2032
- Figure 111: Latin America NGS Oncology Market, $Million, 2021-2032
- Figure 112: Latin America NGS Oncology Market Share (by Country), $Million, 2021 and 2032
- Figure 113: Brazil NGS Oncology Market, $Million, 2021-2032
- Figure 114: Mexico NGS Oncology Market, $Million, 2021-2032
- Figure 115: Rest-of-Latin America NGS Oncology Market, $Million, 2021-2032
- Figure 116: Rest-of-the-World NGS Oncology Market, $Million, 2021-2032
- Figure 117: Total Number of Companies Profiled
- Figure 118: Global NGS Oncology Market: Company Profile Overview
- Figure 119: Agilent Technologies, Inc.: Product Portfolio
- Figure 120: Agilent Technologies, Inc.: Overall Financials, $Million, 2019-2021
- Figure 121: Agilent Technologies, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 122: Agilent Technologies, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 123: Agilent Technologies, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 124: Bio-Rad Laboratories, Inc.: Product Portfolio
- Figure 125: Bio-Rad Laboratories, Inc.: Overall Financials, $Million, 2019-2021
- Figure 126: Bio-Rad Laboratories, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 127: Bio-Rad Laboratories, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 128: Bio-Rad Laboratories, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 129: Biodesix, Inc.: Product Portfolio
- Figure 130: Biodesix, Inc.: Overall Financials, $Million, 2019-2021
- Figure 131: Biodesix, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 132: Biodesix, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 133: Caris Life Sciences: Product Portfolio
- Figure 134: DNASTAR: Product Portfolio
- Figure 135: Fulgent Genetics, Inc.: Product Portfolio
- Figure 136: Fulgent Genetics, Inc.: Overall Financials, $Million, 2019-2021
- Figure 137: Fulgent Genetics, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 138: Fulgent Genetics, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 139: F. Hoffmann-La Roche Ltd: Product Portfolio
- Figure 140: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2019-2021
- Figure 141: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2019-2021
- Figure 142: F. Hoffmann-La Roche Ltd: Revenue (by Region), $Million, 2019-2021
- Figure 143: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2019-2021
- Figure 144: Illumina, Inc.: Product Portfolio
- Figure 145: Illumina, Inc.: Overall Financials, $Million, 2019-2021
- Figure 146: Illumina, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 147: Illumina, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 148: Illumina, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 149: Invitae Corporation: Product/Service Portfolio
- Figure 150: Invitae Corporation: Overall Financials, $Million, 2019-2021
- Figure 151: Invitae Corporation: Revenue (by Segment), $Million, 2019-2021
- Figure 152: Invitae Corporation: Revenue (by Region), $Million, 2019-2021
- Figure 153: Invitae Corporation: R&D Expenditure, $Million, 2019-2021
- Figure 154: IntegraGen (OncoDNA): Product Portfolio
- Figure 155: Oxford Nanopore Technologies plc.: Product Portfolio
- Figure 156: Oxford Nanopore Technologies plc.: Overall Financials, $Million, 2018-2020
- Figure 157: Oxford Nanopore Technologies plc.: Revenue (by Segment), $Million, 2018-2020
- Figure 158: Oxford Nanopore Technologies plc.: Revenue (by Region), $Million, 2018-2020
- Figure 159: Oxford Nanopore Technologies plc.: R&D Expenditure, $Million, 2018-2020
- Figure 160: Pacific Biosciences of California, Inc.: Product Portfolio
- Figure 161: Pacific Biosciences of California, Inc.: Overall Financials, $Million, 2019-2021
- Figure 162: Pacific Biosciences of California, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 163: Pacific Biosciences of California, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 164: Pacific Biosciences of California, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 165: PerkinElmer, Inc.: Product Portfolio
- Figure 166: PerkinElmer, Inc.: Overall Financials, $Million, 2019-2021
- Figure 167: PerkinElmer, Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 168: PerkinElmer, Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 169: PerkinElmer, Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 170: Pillar Biosciences, Inc.: Product Portfolio
- Figure 171: QIAGEN N.V.: Product Portfolio
- Figure 172: QIAGEN N.V.: Overall Financials, $Million, 2019-2021
- Figure 173: QIAGEN N.V.: Revenue (by Segment), $Million, 2019-2021
- Figure 174: QIAGEN N.V.: Revenue (by Region), $Million, 2019-2021
- Figure 175: QIAGEN N.V.: R&D Expenditure, $Million, 2019-2021
- Figure 176: Thermo Fisher Scientific Inc.: Product Portfolio
- Figure 177: Thermo Fisher Scientific Inc.: Overall Financials, $Million, 2019-2021
- Figure 178: Thermo Fisher Scientific Inc.: Revenue (by Segment), $Million, 2019-2021
- Figure 179: Thermo Fisher Scientific Inc.: Revenue (by Region), $Million, 2019-2021
- Figure 180: Thermo Fisher Scientific Inc.: R&D Expenditure, $Million, 2019-2021
- Figure 181: Takara Bio Inc.: Product Portfolio
- Figure 182: Takara Bio Inc.: Overall Financials, $Million, 2018-2020
- Figure 183: Takara Bio Inc.: Revenue (by Segment), $Million, 2018-2020
- Figure 184: Takara Bio Inc.: Revenue (by Region), $Million, 2018-2020
- Figure 185: Takara Bio Inc.: R&D Expenditure, $Million, 2018-2020
- Figure 186: Vela Diagnostics: Product Portfolio
- List of Tables
- Table 1: Impact Analysis of Market Drivers, Challenges, and Opportunities on the Global NGS Oncology Market
- Table 2: Companies Offering Products and Services Using NGS for Hereditary Genetic Testing
- Table 3: NGS Approach for B and T-Acute Lymphoblastic Leukemia (ALL)
- Table 4: NGS-Based Oncology Panel Test
Research Assistance
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook